Ligand-Based and Structure-Based Virtual Screening of New Sodium Glucose Cotransporter Type 2 Inhibitors
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: Diabetes mellitus is a metabolic disease that causes multiple complications and common comorbidities, which decreases the quality of life for people affected by the disease. Sodium glucose cotransporter type 2 (SGLT2) participates in the reabsorption of 90% of glucose in the kidneys; therefore, it is an attractive drug target for controlling blood glucose levels.
OBJECTIVE: The aim in this work was to obtain new potential SGLT2 inhibitors.
METHODS: A ligand-based virtual screening (LBVS) from the ZINC15, PubChem and ChemSpider databases using the maximum common substructure (MCS) scaffold was performed.
RESULT: A total of 341 compounds were obtained and analyzed by molecular docking on the active site of SGLT2. Subsequently, 15 compounds were selected for molecular dynamics (MD) simulation analysis. The compounds derived of spiroketal Sa1, Sa4, and Sa9 (≤ 3.5 Å) in complex with the receptor SGLT2 showed good stability during 120 ns of MD.
CONCLUSION: These compounds are proposed as potential SGLT2 inhibitors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Medicinal chemistry (Shariqah (United Arab Emirates)) - 19(2023), 10 vom: 03., Seite 1049-1060 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Estrada, Ana Karen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Blood glucose |
|---|
| Anmerkungen: |
Date Revised 24.10.2023 published: Print Citation Status Publisher |
|---|
| doi: |
10.2174/1573406419666230803122020 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360345328 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360345328 | ||
| 003 | DE-627 | ||
| 005 | 20231226082823.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1573406419666230803122020 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1201.xml |
| 035 | |a (DE-627)NLM360345328 | ||
| 035 | |a (NLM)37534786 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Estrada, Ana Karen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ligand-Based and Structure-Based Virtual Screening of New Sodium Glucose Cotransporter Type 2 Inhibitors |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 24.10.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: Diabetes mellitus is a metabolic disease that causes multiple complications and common comorbidities, which decreases the quality of life for people affected by the disease. Sodium glucose cotransporter type 2 (SGLT2) participates in the reabsorption of 90% of glucose in the kidneys; therefore, it is an attractive drug target for controlling blood glucose levels | ||
| 520 | |a OBJECTIVE: The aim in this work was to obtain new potential SGLT2 inhibitors | ||
| 520 | |a METHODS: A ligand-based virtual screening (LBVS) from the ZINC15, PubChem and ChemSpider databases using the maximum common substructure (MCS) scaffold was performed | ||
| 520 | |a RESULT: A total of 341 compounds were obtained and analyzed by molecular docking on the active site of SGLT2. Subsequently, 15 compounds were selected for molecular dynamics (MD) simulation analysis. The compounds derived of spiroketal Sa1, Sa4, and Sa9 (≤ 3.5 Å) in complex with the receptor SGLT2 showed good stability during 120 ns of MD | ||
| 520 | |a CONCLUSION: These compounds are proposed as potential SGLT2 inhibitors | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Diabetes mellitus | |
| 650 | 4 | |a SGLT2 | |
| 650 | 4 | |a blood glucose | |
| 650 | 4 | |a inhibitors | |
| 650 | 4 | |a maximum common substructure | |
| 650 | 4 | |a molecular docking | |
| 700 | 1 | |a Mendez-Alvarez, Domingo |e verfasserin |4 aut | |
| 700 | 1 | |a Juarez-Saldivar, Alfredo |e verfasserin |4 aut | |
| 700 | 1 | |a Lara-Ramirez, Edgar E |e verfasserin |4 aut | |
| 700 | 1 | |a Martinez-Vazquez, Ana Veronica |e verfasserin |4 aut | |
| 700 | 1 | |a Villalobos-Rocha, Juan Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Palos, Isidro |e verfasserin |4 aut | |
| 700 | 1 | |a Ortiz-Perez, Eyra |e verfasserin |4 aut | |
| 700 | 1 | |a Rivera, Gildardo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medicinal chemistry (Shariqah (United Arab Emirates)) |d 2005 |g 19(2023), 10 vom: 03., Seite 1049-1060 |w (DE-627)NLM163628467 |x 1875-6638 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2023 |g number:10 |g day:03 |g pages:1049-1060 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1573406419666230803122020 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2023 |e 10 |b 03 |h 1049-1060 | ||